APP and Alzheimer disease: In recent years, the 5LO enzymatic pathway has emerged as a novel candidate gene for neurodegeneration, since, by controlling inflammatory reactions, it acts as an endogenous modulator of brain amyloidosis in transgenic mouse models overexpressing human APP variant21, as well as in the development of the AD-like phenotype of the triple-transgenic mouse model, which develops both Aβ plaques and tau tangles22.